Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial

Fig. 3

Comparison of the mean differences of the cell-mediated responses between days 0 and 14 in the BBIBP-CorV and RCP study groups in a subgroup of 18 participants. P-values for the t-test have been presented in the figures. Error bars are 95% CIs. A Specific cytokines were detected by ELISA (IFN-γ, TNF-α, interleukin 2, interleukin 4, interleukin 17), B lymphocyte proliferative potential response following stimulation by S antigen was measured by CFSE method, and C cell counts for lymphocytic subpopulations (CD3/CD4 ratio, CD3/CD8 ratio) using flow cytometry

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us